Xolair 150 MG/1.2 ML powder VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FQPW4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,688
Award facts
- Contract value 100% obligated
- $23,688.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $23,688.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/1.2 mL powder vials. The award, made on December 9, 2025, with a completion date of December 31, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to supply comprehensive pharmaceutical products to military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a critical pharmaceutical supplier within the federal defense medical supply chain, with the parent IDC valued at $499,999,999 and effective through December 31, 2036. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals including oncology treatments and immunosuppressants. As a single-award regional prime vendor under the PPV-G GEN V framework, DMS Pharmaceutical Group supports the Department of Defense's recurring medical supply requirements across multiple therapeutic categories and has maintained consistent contract performance across numerous delivery orders issued by the Defense Logistics Agency.
Quick answers
Who was awarded contract SPE2DR26FQPW4?
SPE2DR26FQPW4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FQPW4 worth?
The government has obligated $23,688 on SPE2DR26FQPW4.
Is contract SPE2DR26FQPW4 an order under another contract?
Yes. SPE2DR26FQPW4 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPW4 competed?
The extent of competition for SPE2DR26FQPW4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award